Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremia

Basilea Pharmaceutica Ltd, Allschwil announced that data from the successful phase 3 study ERADICATE were published in the New England Journal of Medicine, one of the world’s leading peer-reviewed medical journals.

Scroll to Top